Chris Papadopoulos

Senior Project Manager/ Senior Reseach Scientist Translational Biomarkers at Evotec

Chris Papadopoulos is a highly experienced professional in the field of molecular biology, specializing in translational biomarkers and neuroscience. Currently serving as a Senior Project Manager and Senior Research Scientist at Evotec since May 2019, Chris has extensive experience in project and line management, as well as assay development within multidisciplinary teams. Prior to this role, Chris held postdoctoral positions at the University Duisburg Essen and CECAD Research Center at the University of Cologne, contributing to multiple publications and mentoring doctoral and master’s students. Chris earned a doctoral degree in biology from RWTH Aachen University, where research focused on functional characterization of a protein kinase and results were published in reputable journals. Additionally, Chris has international research experience at the Centre for Genomic Regulation, where work involved investigating neuronal signaling pathways related to trisomy 21.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Evotec

5 followers

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.


Industries

Headquarters

Hamburg, Germany

Employees

1,001-5,000

Links